2022
International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panel
2019
Recipient factors influencing red blood cell alloimmunization
Hendrickson J. Recipient factors influencing red blood cell alloimmunization. ISBT Science Series 2019, 15: 194-200. DOI: 10.1111/voxs.12485.Peer-Reviewed Original ResearchSickle cell diseaseRBC alloantibodiesMyelodysplastic syndromeRed blood cell alloimmunizationRed blood cell alloantibodiesRBC alloantibody formationReductionist murine modelHaemolytic transfusion reactionsType of inflammationHigh prevalence ratesForms of autoimmunityDetectable alloantibodiesRBC alloimmunizationTransfusion avoidanceTransfusion burdenAlloantibody formationAntigen matchingRecipient factorsAntibody screenPatient populationHaemolytic diseaseRBC exposureRisk factorsTransfusion reactionsMurine model